ReCOV – Recombinant Bicomponent COVID-19 Vaccine

ReCOV is a recombinant COVID-19 vaccine developed by the Company comprehensively using its core technology platforms, including its novel adjuvant, protein engineering and immunological evaluation platforms, and the adjuvant used therein is its self-developed novel adjuvant BFA03.

ReCOV vaccine has a variety of comprehensive advantages, including favorable broad-spectrum of neutralizing antibodies and good immune persistence, overall positive safety profile, potential growth in production scale, low production cost, good preparation stability, and ability to be stored and transported at room temperature. In a comparative clinical study with a positive control of the Pfizer’s mRNA vaccine, a sequential booster of ReCOV among subjects who have completed vaccination of inactivated vaccines induced durable and widespread cross-neutralizing antibodies against various Omicron variants, with all subgroups achieving superior levels of neutralizing antibodies as compared to the Pfizer’s mRNA vaccine (with statistically significant differences).

The vaccine has obtained formal marketing authorization from Mongolia. We will adopt a more reasonable follow-up development strategy by taking into account market demand and relevant regulatory guidance.